Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0003319707304145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of haemolysis-induced hyperkalaemia in an extremely low birthweight infant exposed to maternal sulfasalazine.
BMJ Case Rep
January 2025
Neonatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Sulfasalazine is a non-specific immunomodulator with haemolytic anaemia as a known side effect that crosses the placenta. We present a preterm neonate with cardiac arrhythmia secondary to hyperkalaemia in the setting of maternal sulfasalazine therapy. A preterm infant was born to a mother taking hydroxychloroquine, sulfasalazine, aspirin and enoxaparin throughout pregnancy.
View Article and Find Full Text PDFRenal Outcomes With Renin-Angiotensin System Blockers After Unilateral Nephrectomy.
Kidney Int Rep
January 2025
Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Introduction: Despite the benefits of renin-angiotensin system (RAS) blockers, their immediate use after nephrectomy has been limited because of concerns about impaired renal adaptation. We aimed to evaluate the effect of RAS blockers immediately after unilateral nephrectomy on renal adaptation.
Methods: This single-center retrospective cohort study included 580 patients who underwent elective unilateral nephrectomy between 2010 and 2020 and had preexisting hypertension with antihypertensive medications.
Comparison of sodium zirconium cyclosilicate and sodium polystyrene sulfonate in the treatment of acute hyperkalaemia.
Eur J Hosp Pharm
December 2024
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, California, USA
Objective: Sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC) have been used for treating acute hyperkalaemia. The pharmacodynamic properties of SZC suggest greater theoretical utility in the acute setting than SPS, but there is no clear guidance on an optimal potassium binder. This study evaluated the efficacy of SZC and SPS in the treatment of acute hyperkalaemia.
View Article and Find Full Text PDFEffect of Finerenone in Cardiovascular and Renal Outcomes: A Systematic Review and Meta-analysis.
Cardiovasc Drugs Ther
January 2025
Department of Cardiovascular Science, Ascension St, Thomas Hospital, University of Tennessee Health Science Center, Nashville, TN, USA.
Purpose: Heart failure (HF) management is well-defined for reduced ejection fraction (HFrEF) but less so for mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This meta-analysis evaluates the impact of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular and renal outcomes in these patient populations.
Methods: A systematic search in PubMed and Embase identified randomized controlled trials (RCTs) on Finerenone's cardiovascular and renal effects.
Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality.
JACC Adv
November 2024
AstraZeneca, Wilmington, Delaware, USA.
Article Synopsis
- Recurrent hyperkalemia (HK) in patients with chronic kidney disease (CKD) is linked to significantly higher risks of all-cause mortality and cardiovascular (CV) issues compared to patients with normal potassium levels.
- The study involved matching 6,337 patients with recurrent HK to those with normokalemia, adjusting for relevant factors, to ensure a fair comparison.
- Findings indicated that recurrent HK is particularly detrimental, increasing risks for major adverse cardiovascular events (MACE+) and hospitalizations due to arrhythmias, affecting both the overall CKD population and those with co-occurring heart failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!